Kala Pharmaceuticals $126.2 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 16,000,000 shares of common stock…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
McKesson splits off interest in Change Healthcare
Davis Polk advised McKesson Corporation in connection with the offer by McKesson to exchange shares of McKesson common stock for shares of PF2 SpinCo, Inc. (“SpinCo”) common stock owned by…
NanoString Technologies $230 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of $230 million aggregate principal amount of its 2.625% convertible…
Millendo Therapeutics amendments of at-the-market offering program
Davis Polk advised the sales agents in connection with certain amendments of the SEC-registered at-the-market offering program by Millendo Therapeutics, Inc. of up to $50 million gross…
J M Smith sale of smith Technologies to Francisco Partners
Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies, to private equity sponsor Francisco Partners, pursuant to a…
NuVasive $450 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million aggregate principal amount of its 0.375% convertible senior notes due…
Atara Biotherapeutics $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.
Based in…
CytomX Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million…
BioXcel Therapeutics $73.6 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…
Revolution Medicines $273.7 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…